<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83213">
  <stage>Registered</stage>
  <submitdate>26/09/2008</submitdate>
  <approvaldate>24/10/2008</approvaldate>
  <actrnumber>ACTRN12608000537358</actrnumber>
  <trial_identification>
    <studytitle>Metabolic effects of oestrogen compounds in men with low testosterone</studytitle>
    <scientifictitle>Metabolic effects of SERMs (Selective Oestrogen Receptor Modulators) in hypogonadal men</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic effects in men with low testosterone</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Raloxifene (120 mg) as 2 oral tablets  a day for 6 months</interventions>
    <comparator>placebo (sugar pill), 2 tablets a day for 6 month</comparator>
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Growth hormone (GH) secretion after arginine stimulation, measured by GH Elisa kit, Bioclone Australia</outcome>
      <timepoint>At baseline and after 1 and 6 months of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Whole body protein turnover by leucine turnover technique.</outcome>
      <timepoint>At baseline and after 1 and 6 months of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fat and lean body mass by Dual energy xray absorptiometry (DEXA).</outcome>
      <timepoint>At baseline and after 1 and 6 months of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Measurements of fat oxidation by indirect calorimetry</outcome>
      <timepoint>At baseline and after 1 and 6 months of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biochemical markers of growth hormone - insulin-like growth factor I (GH-IGFI) axis measured by radioimmuno assay.</outcome>
      <timepoint>At baseline and after 1 and 6 months of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hypogonadism (prostate cancer patients on androgen deprivation therapy for at least 6 months)</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Androgen deprivation for less than 6 months, metastasis, cancer in other tissues than prostate, diabetes, kidney and liver disease, deep vein thrombosis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>6/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Endocrinology, St Vincent's Hospital</primarysponsorname>
    <primarysponsoraddress>390 Victoria St Darlinghurst, NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC (National Health &amp; Medical Research Council)</fundingname>
      <fundingaddress>Level 5, 20 Allara Street Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We aim to investigate the effects of raloxifene (SERM) in hypogonadal men on the growth hormone system and metabolism.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>390 Victoria St Darlinghurst, NSW 2010</ethicaddress>
      <ethicapprovaldate>5/10/2007</ethicapprovaldate>
      <hrec>H07/070</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Ken Ho, MD, FRACP, Head of Dept of Endocrinology, St Vincent’s Hospital</name>
      <address>Pituitary Research Unit
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst</address>
      <phone>02 9295 8482</phone>
      <fax>02 9295 8481</fax>
      <email>k.ho@garvan.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof Ken Ho, MD, FRACP, Head of Dept of Endocrinology, St Vincent’s Hospital</name>
      <address>Pituitary Research Unit
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst
2010 NSW</address>
      <phone>02 9295 8482</phone>
      <fax>02 9295 8481</fax>
      <email>k.ho@garvan.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Vita Birzniece, MD, PhD</name>
      <address>Pituitary Research Unit
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst
2010 NSW</address>
      <phone>02 9295 8486</phone>
      <fax>02 9295 8481</fax>
      <email>v.birzniece@garvan.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>